AGC Inc. has unveiled plans for a major expansion of facilities at its Chiba Plant in Japan that will result in an approximately tenfold increase in the company’s GMP-compliant synthetic pharmaceutical intermediate and active ingredient production capacity. The new capacity is set to come online in October 2019. AGC began developing and manufacturing pharmaceutical and agrochemical intermediates and active ingredients on a contract basis in the 1980s. Leveraging its edge in fluorine tec...